Related Experiment Video
Updated: Apr 16, 2026
12:10
Retzius-Sparing Robot-Assisted Radical Prostatectomy
Published on: May 19, 2022
10.0K
Variation between specialist uropatholgists in reporting extraprostatic extension after radical prostatectomy
Richard J Bryant1, Anne J Schmitt2, Ian S D Roberts2
1Nuffield Department of Surgical Sciences, University of Oxford, Old Road Campus Research Building (off Roosevelt Drive), Oxford, UK Department of Urology, Oxford University Hospitals NHS Trust, Churchill Hospital, Oxford, UK.
Journal of Clinical Pathology
|March 21, 2015
Summary
Uropathologists show significant variation in assessing extraprostatic extension in prostate cancer radical prostatectomy specimens. This variability impacts patient management, highlighting a need for clearer guidelines in prostate cancer staging.
Area of Science:
- Uropathology
- Oncology
- Surgical Pathology
Background:
- Extraprostatic extension (EPE) in radical prostatectomy (RP) specimens is critical for prostate cancer management.
- Accurate staging of EPE influences treatment decisions and patient prognosis.
Purpose of the Study:
- To evaluate interobserver variation among uropathologists in assessing EPE in RP specimens.
- To identify the extent of disagreement in pT staging of prostate cancer.
Main Methods:
- Review of 293 RP specimens, with a subset of 50 cases reassessed by four specialist uropathologists.
- Double-blind review to assess consensus on EPE and pT staging.
Main Results:
- Significant differences in reported pT stage were observed among pathologists (p=0.0164).
- A lack of consensus was found in 32% of cases (κ score 0.58, moderate agreement).
- Consensus could not be reached in 9 out of 16 cases even after a dedicated meeting.
Conclusions:
- There is notable variability in reporting pT stage for EPE in RP specimens, even among specialists.
- The findings underscore the need for improved standardization and more precise guidance in assessing EPE.
- Standardized assessment of EPE is crucial for consistent patient management in prostate cancer.
